ME1 great news and more to come -- 12 October 2023Wholly-owned...

ME1 great news and more to come --
12 October 2023
Wholly-owned subsidiary Halucenex Life Sciences Inc. achieves
remission in 80% of first five patients in Phase II clinical trial
Highlights:
• Encouraging early results from Phase II clinical trial to test the efficacy of psilocybin on treatmentresistant Post Traumatic Stress Disorder (PTSD)
• Five patients have undergone testing to date with 80% of participants experiencing total remission
from PTSD symptoms following two doses of Halucenex’s 100%-owned synthetic psilocybin aqueous
solution Lucenex
• Additional results from first five patients include:
o 50% reduction in anxiety scores from baseline to day 44 of treatment
o 57% reduction in depression scores from baseline to day 44 of treatment
• Initial results are positive given conventional treatments for anxiety and depression are only around
20-30% effective